JUBILANT PHARMOVA LIMITED’s– Q3 & 9M’FY23 FINANCIAL RESULTS
The Board of Jubilant Pharmova Limited met recently to approve financial result for the quarter ended December 31, 2022.
Commenting on Company’s Performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said:
'During the quarter, Company reported higher revenues YoY led by increase in sales in Radiopharmacies, Allergy and CDMO-API businesses and stable revenues in Radiopharmaceuticals, CDMO Sterile Injectables and Drug Discovery Services businesses.
Company’s profitability stood lower in Q3’FY23 vs. YoY and QoQ due to lower Covid related deals in CDMO Sterile Injectables business, industry wide issue of generator supply outage that impacted Radiopharmacies business, lower production in CDMO-API business and lower volumes in Drug Discovery Services business. In Generics, the Company has undertaken a large scale business transformation focused on turnaround through cost optimisations and driving growth in branded markets in India and select international markets. In FY24, Company’s profitability is expected to improve driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in Generics, API businesses and Radiopharmacies will also contribute to better profitability. The Company has several growth levers across its various businesses (Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics and CRDMO), which shall drive sustainable growth for the company in the medium term. In our Proprietary Novel Drugs business we have several high potential programs, which are at the preclinical / clinical stage.'
For more info please click here.
Jubilant’s Radiopharma Business Receives NDA Approval for Technetium Mertiatide Injection
Jubilant Draximage Inc recently received approval from the US FDA with regards to the Company’s new drug application (NDA) submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kit for the Preparation of Technetium (Tc 99m) Mertiatide Injection
For more info click here.
Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)
Jubilant Therapeutics Inc., recently announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for JBI-778 for the treatment of Glioblastoma Multiforme (GBM). JBI-778 is an oral, brain penetrant and substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor for the treatment of tumors with brain metastases and primary brain tumors including high-grade glioma. JBI-778 is the Company’s second drug candidate to receive ODD along with JBI-802, which received ODD for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).
For more info please click here.
Location - Bengaluru
Kutumba Card Launch
Jubilant Biosys Limited have partnered with Sparsh Hospital, Yeshwanthpur, for Medical Emergency Assistance to its employees. In continuation to our partnership, Sparsh Hospital is extending its 'Kutumba Card' to the employees of Jubilant for OPD, inpatient & medical tests. The Benefit of this Kutumba card is employees and their family members will be able to avail discounts from the hospital. The launch of the card happened on 25th January 2023 at our Premises.
